Precision Oncology News

Drug Discovery & Development

News on drug screening, clinical trials, companion diagnostics, immunotherapy, & personalized therapies in genetics, genomics, and molecular diagnostics.

JP Morgan Healthcare, Day 4: Five Prime Therapeutics and Gritstone Oncology

Five Prime Therapeutics provided an update on the development of bemarituzumab and FPA150, and Gritstone Oncology discussed plans for its personalized immunotherapies.

In Precision Oncology, Drugs Coming to Market Based on Smaller, Early-Phase, Single-Arm Trials

Premium

Increasing understanding of complex tumor biology is reshaping clinical trials in the age of precision medicine, though some view these changes with concern.

FDA Accepts Clovis Oncology's Supplemental Drug Application for Rubraca in Advanced Prostate Cancer

The FDA granted priority review status to rucaparib for prostate cancer patients with BRCA1/2 mutations.

JP Morgan Healthcare, Day 1: Agios Pharmaceuticals, Clovis Oncology, Mirati Therapeutics, and More

Among the firms presenting, drugmakers, speciality biotechs, and genetic testing firms provided an update on their precision oncology development programs.

Iovance, Cellectis to Develop Cancer Treatment Based on Genetically-Edited Lymphocytes

The worldwide license provides Iovance Biotherapeutics exclusive rights to Cellectis' TALEN gene editing technology for multiple gene targets to modify TILs for treating various cancers.

Jan 13, 2020

Adaptive Biotechnologies, Genentech Partner on MRD Testing in Venetoclax Clinical Trial

Jan 09, 2020

FDA Accepts IND of NK Cell Therapy for HER2 Positive Solid Tumors

Jan 08, 2020

Blueprint Reports High Response Rates From Lung Cancer Patients in Early Pralsetinib Trials

Jan 07, 2020

AI-based Immunotherapy for Ovarian, Head and Neck Cancers Evaluated in Two Phase I Trials

Jan 06, 2020

Blueprint, CStone Enroll First Patient in Phase Ib/II Trial for FGFR4-Driven Liver Cancer

Dec 30, 2019

Eli Lilly Opens Phase III Trial for RET-Mutant Medullary Thyroid Cancer

Dec 27, 2019

Spectrum's Poziotinib Failed to Meet Primary Phase II Trial Endpoint

Dec 27, 2019

FDA Grants Orphan Drug Status to OBI's Targeted Pancreatic Cancer Therapy

Dec 24, 2019

CytoDyn Sees Promising Early Responses in Two Breast Cancer Patients to Leronlimab

Dec 20, 2019

Bridge Biotherapeutics Files IND for Lung Cancer Drug Targeting EGFR Resistance Mutation

Dec 13, 2019

Gritstone Oncology Debuts Positive Phase I Safety Data for 'Next-Generation' Cancer Immunotherapy

Premium

Dec 12, 2019

Immunotherapy Regimens Yield Contrasting Results in Early Triple Negative Breast Cancer

Premium

Dec 12, 2019

Seattle Genetics Presents Positive Tucatinib Phase II Data for HER2-Positive Breast Cancer

Dec 12, 2019

Molecular Subgroup May Benefit From Less Toxic CDK4/6 Treatment in ER+ Neoadjuvant Setting

Dec 11, 2019

Eli Lilly Opens Phase III Trial for RET Fusion-Positive Non-Small Cell Lung Cancer Drug

Dec 11, 2019

Benefit Holds Up for Dual Adjuvant HER2 Treatment in Updated Trial Results

Dec 10, 2019

Vedanta, Bristol-Myers Squibb to Study Immuno-oncology Combo Therapy for Variety of Cancers

Dec 09, 2019

Kura Oncology Reports Positive Interim Data From Phase II Tipifarnib Trial for T-Cell Lymphoma

Dec 05, 2019

AstraZeneca, Merck's Lynparza Approved in China for BRCA-Mutated Ovarian Cancer

Dec 04, 2019

Genentech Garners FDA Approval for Tecentriq in Front-Line Lung Cancer Regardless of PD-L1 Status